Clinical trials
Cholangiocarcinoma clinical trials
Below are recruiting cholangiocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 185 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07063888RecruitingPhase 2
Chemoradiation after surgery for bile duct cancer
This trial tests whether combining chemotherapy with radiation after surgery can help prevent the return of intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is for people whose surgery showed a narrow margin or cancer in nearby lymph nodes.
BeijingAges 18–80 - NCT07070700RecruitingPhase 2
Cryoablation with targeted therapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07105748RecruitingPhase 2
HAIC plus Camrelizumab and Rivoceranib for advanced mixed liver-bile duct cancer
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07105852RecruitingPhase 2
A new drug combo for advanced bile duct cancer
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07206355Recruiting
Studying bile duct and liver lesions for new cancer tests
This study looks at tissue samples from people with bile duct, liver, or pancreas problems to develop better ways to detect cancers in these areas. If you are scheduled for a biopsy, scan, or surgery for a suspected growth in your liver, pancreas, or bile duct, you may be able to help.
NottinghamAges 16 years+ - NCT07235007Recruiting
New treatment for bile duct cancer with heat, immunotherapy, and chemo
This trial tests a combination of heat therapy inside the bile duct (endobiliary RFA) with immunotherapy (durvalumab) and chemotherapy (gemcitabine and cisplatin) for people with unresectable extrahepatic cholangiocarcinoma. The goal is to see if adding the heat treatment improves outcomes.
AichiAges 18 years+ - NCT06101277Recruiting
Local therapy for limited new cancer growth in digestive cancers
This trial tests a cancer treatment that uses local therapies (like radiation or targeted heat) to destroy a small number of growing spots. It is for people with certain gastrointestinal cancers whose main treatment is working well except for a few new spots, so they can avoid switching to a different drug right away.
Sacramento, CaliforniaAges 18 years+ - NCT07570849RecruitingPhase 2
Chidamide with chemotherapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07632235RecruitingPhase 1/Phase 2
Celecoxib with immunotherapy for bile duct cancer
This trial tests whether adding celecoxib (an anti-inflammatory pill) to pembrolizumab (an immunotherapy) and chemotherapy helps treat intrahepatic cholangiocarcinoma—a type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than the standard two-drug approach.
ShanghaiAges 18 years+ - NCT07636824RecruitingPhase 2
Chemotherapy plus radiation after bile duct cancer surgery
This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.
BeijingAges 18–80 - NCT07640048Recruiting
Adjuvant therapy after surgery for high-risk bile duct cancer
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
BeijingAges 18 years+ - NCT06997913Enrolling by invitation
Immunotherapy and chemoradiation after bile duct cancer surgery
This trial tests whether combining immunotherapy with chemotherapy and radiation after surgery can help prevent bile duct cancer from coming back in people who have a high risk of recurrence.
XiAn, ShanxiAges 18–70 - NCT06901622Enrolling by invitationPhase 2
Testing a combination of drugs for advanced gallbladder and bile duct cancer
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
ZhengzhouAges 18–75 - NCT06474091Enrolling by invitation
Blood monitoring for bile duct cancer treatment and outlook
This trial uses a simple blood test to track how well bile duct cancer responds to treatment and to predict outcomes. It may help doctors make better decisions about surgery and other therapies.
Rochester, MinnesotaAges 18 years+ - NCT05404503Enrolling by invitation
Check how often bile-duct cancer happens in choledochal cysts
This study looks at how frequently cholangiocarcinoma (bile-duct cancer) occurs in people with choledochal cysts (a swelling of bile ducts). It mainly uses existing imaging records to understand risk in a hospital population.
HuelvaAges Any age - NCT04195503Enrolling by invitation
Liver transplant for stable advanced bile duct cancer
This trial looks at liver transplant for people with advanced intrahepatic cholangiocarcinoma (a bile duct cancer inside the liver) when the cancer is not safely removable and stays controlled. It may help some patients live longer and with better quality of life by replacing the diseased liver—if strict safety and disease-stability requirements are met.
Toronto, OntarioAges 18 years+ - NCT07760038Recruiting
Phycocyanin for liver protection before partial liver removal
This trial tests whether phycocyanin, a natural supplement, can protect the liver before and after surgery to remove part of the liver. It is for people with a type of bile duct cancer who are already getting chemotherapy and other treatments before surgery.
Hangzhou, ZhejiangAges 18–75 - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06462742Recruiting
Microwave ablation vs. surgery for intrahepatic cholangiocarcinoma
This trial compares two treatments for a liver cancer called intrahepatic cholangiocarcinoma—surgery to remove the tumor versus microwave ablation, which uses heat to destroy cancer cells. It tests if ablation works as well as surgery for people with small tumors that haven't spread.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06280508RecruitingPhase 2
Perioperative chemo plus immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
Guangzhou, China/GuangdongAges 18 years+ - NCT05978609RecruitingPhase 2
Testing cadonilimab plus chemotherapy for advanced bile duct cancer
This trial tests a new combination therapy for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. It combines a drug called cadonilimab with standard chemotherapy to see if it works better than chemotherapy alone.
Chengdu, SichuanAges 18–75 - NCT05265208RecruitingPhase 2
Radiation plus chemo after liver surgery for bile duct cancer
This trial studies giving a special internal radiation treatment along with capecitabine (a chemotherapy) for liver cancer related to bile ducts, after planned surgical removal. It may help improve control of the cancer in cases where surgeons think the edges of the removed tumor may be too close.
Rennes, Brittany RegionAges 18 years+ - NCT06168292Recruiting
Combined treatment for bile duct cancer
This trial is testing a new approach for people with bile duct cancer that cannot be removed by surgery. It combines a procedure that uses heat to destroy cancer cells inside the bile duct with standard radiation therapy.
Goyang-si, OtherAges 20 years+ - NCT06050252RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk bile duct cancer
This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine and cisplatin) before surgery helps people with a high-risk type of bile duct cancer live longer. If you qualify, you would receive the drug combination before your planned surgery.
Irvine, CaliforniaAges 18 years+
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangiocarcinoma?
- Yes. Clin2 currently lists 185 recruiting cholangiocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangiocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangiocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.